Introduction
Throughout the history of the world, the ones who had confronted the bitterest face of poverty and war had always been the women. As known poverty and war affects human health either directly or indirectly, the effects of this condition on health and status of women in the society should not be ignored. This study intends to cast light on the effects of war and poverty on the reproductive health of women. For this purpose, the face of war affecting the women, the problem of immigration, inequalities in distribution of income based on gender and the effects of all these on the reproductive health of women will be addressed.
War and Women's Health
Famine, synonymous with war and poverty, is clearer for women; war means deep disadvantages such as full destruction, loss of future and uncertainty for women. Wars are conflicts that destroy families, societies and cultures that negatively affect the health of community and cause violation of human rights. According to the data of World Health Organization (WHO) and World Bank, in 2002 wars had been among the first ten reasons which killed the most and caused disabilities. Civil losses are at the rate of 90% within all losses (1). War has many negative effects on human health. One of these is its effect of shortening the average human life. According to the data of WHO, the average human life is 68.1 years for males and 72.7 years for females. It is being thought that severe military conflicts in Africa shorten the expected lifetime for more than 2 years. In general, WHO had calculated that 269 thousand people had died in 1999 due to the effect of wars and that loss of 8.44 million healthy years of life had occurred (2, 3) . Wars negatively affect the provision of health services. Health institutions such as hospitals, laboratories and health centers are direct targets of war. Moreover, the wars cause the migration of qualified health employees, and thus the health services hitches. Assessments made indicate that the effect of destruction in the infrastructure of health continues for 5-10 years even after the finalization of conflicts (3) . Due to resource requirements in the restructuring investments after war, the share allocated to health has decreased (1).
Mortalities and Morbidities
The ones who are most affected from wars are women and children. While deaths depending on direct violence affect the male population, the indirect deaths kill children, women and elders more. In Iraq between 1990-1994, infant deaths had shown this reality in its more bare form with an increase of 600% (4). The war taking five years increases the child deaths under age of 5 by 13%. Also 47% of all the refugees in the world and 50% of asylum seekers and displaced people are women and girls and 44% refugees and asylum seekers are children under the age of 18 (5) . As the result of wars and armed conflicts, women are
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Materials and Methods
This was a single-blind randomized study, which was performed at Milad hospital of Mashhad, Iran between February 2015 and February 2016.
PCOS patients who were resistant to clomiphene or letrozole in 2 previous cycles (no ovarian response to induction ovulation) and aged between 20 and 40 were included in the study. PCOS diagnosis was made according to the 2003 Rotterdam consensus criteria (7), i.e. to have 2 of the following three criteria: 1) ovulation dysfunction (sporadic ovulation or no ovulation) occurred after continuous monitoring for 2 or more natural cycles; 2). The results of the ultrasound showing polycystic ovaries; 3) hyperandrogenism, clinical or subclinical manifestations of androgen excess after ruling out hyperandrogenism caused by other diseases such as adrenal hyperplasia, Cushing syndrome and androgen-secreting tumors. This study has been approved by the ethics committee of the hospital, and informed consent was obtained from all patients. All cases were confirmed to have tubal patency (at least one tube) in hystrosalpingography and normal semen analysis. Patients with a history of ovarian surgery or complicated endometriosis, pelvic adhesion, liver, kidney, thyroid or prolactin dysfunction and smokers were excluded from the study. The PCOS patients were randomly divided into letrozole + R-FSH group (n = 59) and letrozole + HMG group (n = 59).
Randomization
All infertile women with PCOS who failed to ovulate with CC were individually counseled about the study and the protocols by a coordinator. After obtaining written consent they were allocated to one of 2 groups (A or B) via simple random sampling by the same coordinator. Group A (n = 59) received 2.5 mg of letrozole (Letrax, Aborayhan, Iran) twice daily for 5 days, starting on day 3 of the menstrual cycle and HMG 75 IU (Menopur, Ferring S.A., Madrid, Spain) was subcutaneously started on day 8 and was continued till the follicles size reached 15 mm. Group B (n = 59) received 2.5 mg of letrozole (Letrax, Aborayhan, Iran) twice daily for 5 days, starting on day 3 of the menstrual cycle and r-FSH 75 IU (Gonal F, Serono, Madrid, Spain) was subcutaneously started on day 8 and continued till the follicles size reached 15 mm. All patients were monitored for ovarian follicular development and endometrial thickness with transvaginal ultrasound on the 10th day of menstrual cycle. 250 µg of recombinant human chorionic gonadotropin (hCG) (Ovitrelle, Serono, Madrid, Spain) was subcutaneously administered as a single dose when the average diameter of the leading follicles reached ≥18 mm (up 2 follicles). IUI was performed 36 hours later. Luteal phase was supported with the progesterone suppository (400 mg) (Cyclogest, Actavis, Barnstaple, UK) daily for 15 days. Clinical pregnancy rate were the primary outcomes. Abortion and live birth were the secondary outcomes. Chemical pregnancy was confirmed through the analysis of serum βhCG 14 days after IUI. Abortion was defined as loss of pregnancy before 20 weeks of gestation. Clinical pregnancy was defined as the presence of a gestational sac with cardiac activity as detected by transvaginal ultrasound.
Statistical Analysis Data were analyzed using SPSS software version 16.0 (SPSS Inc., Chicago. IL). Student's t-test and chi-square test were used to analyze the obtained data. P<0.05 was considered statistically significant.
Results
A total of 130 consecutive patients (65 patients in group A and 65 patients in group B) meeting the inclusion criteria during the period from February 2015 to February 2016 were enrolled in this study. Six patients in group A and 6 patients in group B did not complete the treatment cycles and were excluded from the study (Figure 1 ). Demographic characteristics including age, duration of infertility, type of infertility and body mass index (BMI) are summarized in Table 1 and no significant difference was observed in 2 groups (P > 0.05). The number of follicles ≥18 mm at the time of hCG administration and the duration of follicular stimulation showed no difference in the 2 groups. The total dose of gonadotropins and endometrial thickness were similar in the 2 groups (Table 2) . Pregnancy rates were different in the 2 groups (8.5% and 22% in the group A and B, respectively) (P=0.04). There were not any significant differences in the abortion rate, twin pregnancies and live birth rate in 2 groups (Table 2) . No cases of cycle cancelation or OHSS were reported in 2 groups.
Discussion
The strong point of our study is that it is the first randomized, prospective, single-blind clinical trial that administered the combination of letrozole with HMG 
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and with R-FSH for controlled ovarian stimulation in IUI cycle in PCOS patients. The rate of clinical and chemical pregnancy in the group B (letrozole + R-FSH) was higher than in the group A (letrozole + HMG). Both letrozole and gonadotropin have been used alone in infertile women. Results suggest that aromatase inhibitor (letrozole) can be as effective as clomiphene and thus can be used as first-line treatment for ovarian stimulation. Letrozole seems to have a lower risk of multiple gestation (11) and OHSS (12) .
PCOS patients who are resistant to clomiphene respond primarily to smaller dosages of gonadotropin. These women are also more sensitive to medication and the treatment range is narrow for them. If the dosage goes slightly higher, it will cause OHSS. Theoretically, recombinant FSH is more useful than HMG because it prevents excessive increase of LH in PCOS patients (11) . There is little research on the comparison of letrozole in combination with 2 different gonadotropins (HMG and R-FSH) in PCOS patients. The study of Yun et al on the combined administration of gonadotropins and clomiphene or letrozole in the IUI cycle showed that the efficacy was higher when combined with HMG (6) . Previous studies showed that treatment with letrozole reduced the dosage of HMG required and duration of treatment more effectively and significantly (11, 12) . Torabizadeh and Mirzaian reported that treatment of PCOS patients with different ovulation induction methods such as FSH, HMG or the combination of these medications did not make any difference to pregnancy outcomes (13) . Zhao et al argued that letrozole plus purified HMG was a safe and effective method for clomiphene-resistant patients (14). Athwal et al showed that letrozole plus FSH was an effective treatment for stimulation of ovulation in infertile women (15). The present study showed that the rate of clinical and chemical pregnancy was higher in group B (letrozole + R-FSH) than in group A (letrozole + HMG). Because of the increase of LH in PCOS patients (16) and also the early increase of LH in plasma and follicular fluid, the growth of granulosa cells of antral follicles will decrease and follicular degeneration will rise (11) . Therefore, administration of letrozole + R-FSH seems to be more effective than letrozole + HMG by inhibiting the early increase of endogen LH level. Research limitations include lack of LH level measurements before and after the intervention and small sample size that are recommended to be addressed in future research.
Conclusions
Administration of the combination of Letrozole and r-FSH seems to be a proper treatment in PCOS patients resistant to clomiphen citrate (CC) in comparison to many other therapeutic regimens including HMG or letrozole + HMG with no more prevalent side effects.
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